FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ALEXANDRIA REAL ESTATE EQUITIES, INC.		 2. Issuer Name and Ticker or Trading Symbol

Applied Therapeutics Inc. [ APLT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

26 NORTH EUCLID AVENUE		 3. Date of Earliest Transaction (MM/DD/YYYY)

3/27/2020
(Street)

PASADENA, CA 91101
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 3/27/2020  J(1)  975000 (1)A (1)2146599 I By subsidiary (2)
Common Stock 3/27/2020  J(1)  975000 (1)D (1)1243977 I By subsidiary (3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc.
(2) These shares are held directly by AVI.
(3) These shares are held directly AE7.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
ALEXANDRIA REAL ESTATE EQUITIES, INC.
26 NORTH EUCLID AVENUE
PASADENA, CA 91101
X

Alexandria Venture Investments, LLC
26 NORTH EUCLID AVENUE
PASADENA, CA 91101
X

Alexandria Equities No. 7, LLC
26 NORTH EUCLID AVENUE
PASADENA, CA 91101
X
Signatures
By: /s/ Dean A. Shigenaga Chief Financial Officer ALEXANDRIA EQUITIES NO. 7, LLC By: ARE-Special Services, LLC, managing member3/27/2020
**Signature of Reporting PersonDate

By: ALEXANDRIA REAL ESTATE EQUITIES, L.P., managing member By: ARE-QRS CORP., general partner By: /s/ Dean A. Shigenaga, Chief Financial Officer3/27/2020
**Signature of Reporting PersonDate

ALEXANDRIA EQUITIES NO. 7, LLC By: ARE-Special Services, LLC, managing member By: ALEXANDRIA REAL ESTATE EQUITIES, L.P., managing member By: ARE-QRS CORP., general partner By: /s/ Dean A. Shigenaga, Chief Financial Officer3/27/2020
**Signature of Reporting PersonDate
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Applied Therapeutics
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Applied Therapeutics